- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04280471
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
An Open-Label Phase 1 Pilot Study: Fecal Microbiota Transplantation (FMT) in Severe Acute Gut Graft-Versus-Host Disease Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. For safety evaluation, episodes of microbial bloodstream infection attributed to fecal microbiota transplantation (FMT) within the first 7 days after start of each FMT administration.
II. For tolerability evaluation, subject must ingest 50% of one dose of FMT product without grade 3 or higher adverse events (AEs) within the first 7 days post-FMT.
SECONDARY OBJECTIVE:
I. To collect stool, oral swabs and blood specimens for future studies to define bacterial taxa diversity, microbial translocation as well as metabolomic and proteomic changes associated with the development of graft versus host disease (GvHD).
II. For clinical efficacy, > 50% of subjects with at least 1 stage of gut GvHD improvement by 8 weeks after the first dose of FMT.
OUTLINE:
Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days. Standard treatment for gut GvHD will continue during this time.
After completion of study treatment, patients are followed for up to 6 months.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ashley Gray, M.D.
- Phone Number: 310-825-6708
- Email: ashleygray@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Contact:
- Ashley Gray, M.D.
- Phone Number: 310-825-6708
- Email: ashleygray@mednet.ucla.edu
-
Principal Investigator:
- Grace Aldrovandi, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who received an allogenic hematopoietic stem cell transplantation (HSCT)
- Acute GvHD defined as experiencing GvHD symptoms starting prior to day +100 after HSCT
Gut GvHD defined as subjects experiencing GvHD symptoms consistent with stage 3 or stage 4 by Center for International Blood and Marrow Transplant Research (CIBMTR) staging:
- Stage 3 acute gut GvHD subjects having 1500-1999 mL stool per day
- Stage 4 subjects having greater than 2 liters of stool per day and/or severe abdominal cramping, bleeding or ileus
- Steroid-refractory acute gut GVHD defined as progression of symptoms after 3 days of systemic steroids (> 1 mg/kg/day methylprednisolone) or steroid-resistant acute gut GvHD defined stable symptoms after 5 days of systemic steroids (> 1 mg/kg/day methylprednisolone)
- Able to swallow capsules without aspiration or dysphagia
- Ability to understand the written informed consent and the willingness to sign the consent and accept the risk of receiving unrelated donor stool
Exclusion Criteria:
- Absolute neutrophil count < 500 cells/uL
- Presence of recurrent Clostridium difficile infection
- Presence of ileus or toxic megacolon
- History of multi-drug resistant stool pathogen
- History of inflammatory bowel disease (i.e Crohn's disease or ulcerative colitis)
- Uncontrolled and active systemic infection from bacteria, virus or fungus
- Human immunodeficiency virus (HIV)-positive subjects
- Quantifiable cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) evaluated by polymerase chain reaction (PCR) after hematopoietic stem cell transplantation (HSCT) and after neutrophil engraftment defined as absolute neutrophil count (ANC) > 500 cells/uL
- Hemodynamically unstable
- Active gastrointestinal bleed
- Pregnant and/or breastfeeding women
- Dysphagia due to oropharyngeal, esophageal, functional, neuromuscular (e.g. stroke, multiple sclerosis, amyotrophic lateral sclerosis [ALS]) or subject shows evidence of dysphagia when the 'safety test' capsule is administered
- Delayed gastric emptying syndrome
- Known chronic aspiration
- Subjects with a history of significant allergy to foods
- Subjects with allergies to sodium chloride, glycerol, theobroma oil, hide bovine gelatin, sodium lauryl sulfate, colorants Federal Food, Drug, and Cosmetic Act (FD&C), or titanium dioxide, all ingredients generally recognized as safe (GRAS)
- History of previous gastrointestinal surgery
- Subjects who are receiving other investigational agents for treatment of gut GvHD
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (OpenBiome FMT capsule DE)
Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days.
One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules.
If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.
|
Receive OpenBiome FMT Capsule DE PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 6 months
|
For safety evaluation, episodes of microbial bloodstream infection attributed to fecal microbiota transplantation (FMT) within the first 7 days after start of each FMT administration.
For tolerability evaluation, at least 60% of subjects able to ingest 50% of one dose of FMT without grade 3 or higher adverse events (AEs) within the first 7 days post-FMT.
Subjects will be monitored via assessment of gut graft versus host disease (GvHD) staging and adverse events will be performed bi-weekly for the first 4 weeks after the first dose of FMT, weekly during the hospitalization and monthly up to six months after hospital discharge.
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collection of stool, oral swabs and blood specimens to define bacterial taxa diversity, microbial translocation as well as metabolomic and proteomic changes associated with the development of graft versus host disease (GvHD)
Time Frame: Up to 6 months
|
Alpha diversity metrics will be compared between time points mixed effect regression models.
Multivariate differences will be calculated using permutational multivariate analysis of variance (PERMANOVA).
Differential abundance techniques will be used to compare taxa over time using DESeq2 package.
DESeq2 models taxa counts with a negative binomial model.
To look specifically at before and after FMT, we will apply multivariate techniques such as principal coordinate analysis (PCoA) to identify parameters that are affected positively by FMT and to determine whether these differences persist over time.
The PERMNOVA technique will be applied to survey population-level differences before & after FMT.
We will use the Benjamini-Hochberg false discovery rate (FDR) to account for multiple hypothesis testing.
|
Up to 6 months
|
GvHD improvement
Time Frame: Up to 8 weeks after the first dose of FMT
|
Clinical efficacy will be defined as > 50% of subjects with at least 1 stage of gut GvHD improvement by 8 weeks after the first dose of FMT.
|
Up to 8 weeks after the first dose of FMT
|
Collaborators and Investigators
Investigators
- Principal Investigator: Grace Aldrovandi, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-001736 (Other Identifier: UCLA / Jonsson Comprehensive Cancer Center)
- NCI-2020-00211 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Graft Versus Host Disease
-
University of LiegeTerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host DiseaseBelgium
-
Mesoblast, Inc.Quintiles, Inc.CompletedGrade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host DiseaseUnited States
-
Jazz PharmaceuticalsCompletedAcute-graft-versus-host Disease | Graft-versus-host DiseaseUnited States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
-
AltruBio Inc.CompletedSteroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host DiseaseUnited States
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdNot yet recruitingAcute Graft-Versus-Host DiseaseChina
-
ASC TherapeuticsNot yet recruitingAcute-graft-versus-host Disease
-
The First Affiliated Hospital of Soochow UniversityRecruiting
-
Genentech, Inc.Completed
-
Genentech, Inc.TerminatedAcute Graft-versus-host DiseaseUnited States, Canada
Clinical Trials on Fecal Microbiota Transplantation Capsule
-
M.D. Anderson Cancer CenterRecruitingPancreatic Ductal AdenocarcinomaUnited States
-
Fred Hutchinson Cancer CenterRecruitingAcute Graft Versus Host Disease | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Madhusudan (Madhu) Grover, MBBSRecruiting
-
Medical University of GrazBristol-Myers SquibbTerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota TransplantationAustria
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityNot yet recruitingAttention-deficit/Hyperactivity DisorderChina
-
The Second Hospital of Nanjing Medical UniversityNot yet recruiting
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityNot yet recruitingAutism Spectrum Disorder
-
The Second Hospital of Nanjing Medical UniversityRecruitingCancer | Intestinal ComplicationsChina
-
The First Affiliated Hospital of Nanchang UniversityCompletedAcute Pancreatitis | Intestinal Bacteria Flora Disturbance | Fecal Microbiota Transplantation | Intestinal DysfunctionChina